Information Provided By:
Fly News Breaks for September 2, 2019
ALNY, MDCO
Sep 2, 2019 | 19:32 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam (ALNY) to $145 from $142 after partner The Medicine Co. (MDCO) presented positive Phase III ORION-11 data on inclisiran in 1,617 ASCVD patients at the European Society of Cardiology Congress in Paris. The analyst remains confident in inclisiran approval next year and Alnylam is eligible for milestones plus up to double-digit royalties. He reiterates an Overweight rating on Alnylam shares.
News For MDCO;ALNY From the Last 2 Days
There are no results for your query MDCO;ALNY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.